Astera Labs (ALAB) CFO receives 11,787 RSU equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Astera Labs, Inc. reported an equity award for its Chief Financial Officer, Tate Michael Truett. On February 6, 2026, he received 11,787 restricted stock units of Common Stock at a price of $0 per share, increasing his directly held Common Stock to 204,084 shares.

The RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, conditioned on his continued service. Separately, 450,281 Common Stock shares are held indirectly by the Tate 1997 Living Trust, where he is a trustee and disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Tate Michael Truett

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,787	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 204,084 shares (Direct); Common Stock — 450,281 shares (Indirect, By Tate Trust)

Footnotes (1)

These shares represent an award of restricted stock units ("RSUs") granted on February 6, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on February 15, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

02/10/2026 - 06:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tate Michael Truett

(Last)

(First)

(Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE

95131

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/06/2026		A		11,787⁽¹⁾	A	$0	204,084	D
Common Stock								450,281	I	By Tate Trust⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent an award of restricted stock units ("RSUs") granted on February 6, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on February 15, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Astera Labs (ALAB) disclose for its CFO?

Astera Labs disclosed that CFO Tate Michael Truett received 11,787 restricted stock units of Common Stock on February 6, 2026, at a price of $0 per share. This equity grant increased his directly held Common Stock to 204,084 shares following the transaction.

How do the 11,787 RSUs granted to the Astera Labs CFO vest?

The 11,787 RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments. Vesting is subject to the CFO maintaining a continuous service relationship with Astera Labs through each applicable vesting date.

What is the total direct Common Stock holding of the Astera Labs CFO after this grant?

After the February 6, 2026 grant, the Astera Labs CFO beneficially owns 204,084 shares of Common Stock directly. This figure reflects the reported non-derivative holdings following the RSU award and is separate from any indirectly held shares.

What shares of Astera Labs stock are held through the Tate Trust?

The filing shows 450,281 shares of Astera Labs Common Stock held indirectly through the Tate 1997 Living Trust. The CFO is a trustee of this trust and expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest.

Under which plan were the Astera Labs CFO’s RSUs granted?

The 11,787 RSUs granted to the Astera Labs CFO were issued under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of Astera Labs’ Common Stock upon satisfaction of the vesting conditions.

Does the Astera Labs CFO fully own the shares held by the Tate Trust?

The CFO does not claim full beneficial ownership of shares held by the Tate Trust. The filing states he disclaims beneficial ownership of those securities, except for any pecuniary interest, even though he serves as a trustee of the Tate 1997 Living Trust.